Alexis Desieno Sells 25,118 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares in the company, valued at approximately $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alexis Desieno also recently made the following trade(s):

• On Wednesday, October 2nd, Alexis Desieno sold 7,487 shares of Cardlytics stock. The shares were sold at an average price of $3.08, for a total value of $23,059.96.

Cardlytics Price Performance

CDLX stock opened at $3.38 on Friday. The company’s 50-day moving average price is $3.72 and its two-hundred day moving average price is $6.37. The firm has a market cap of $171.77 million, a P/E ratio of -0.55 and a beta of 1.61. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s revenue was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.26) EPS. On average, analysts anticipate that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Lake Street Capital lowered shares of Cardlytics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI began coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Finally, Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Cardlytics currently has a consensus rating of “Hold” and a consensus target price of $6.92.

Institutional Trading of Cardlytics

Hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after buying an additional 1,774 shares in the last quarter. Canton Hathaway LLC increased its holdings in Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after purchasing an additional 2,200 shares in the last quarter. Check Capital Management Inc. CA increased its holdings in Cardlytics by 10.4% in the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock worth $162,000 after purchasing an additional 4,775 shares in the last quarter. BNP Paribas Financial Markets raised its position in Cardlytics by 32.1% in the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after purchasing an additional 4,796 shares during the last quarter. Finally, Creative Planning boosted its stake in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.